NCT06540833招募中2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI 1284 in Patients With Psychosis Associated With Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 370
- 试验地点
- 80
- 主要终点
- BEHAVE-AD psychosis subscale score
研究概览
简要总结
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.
详细描述
The study will be conducted in 3 periods:
- Screening Period (up to 4 weeks) during which patient eligibility will be assessed;
- Double-blind Treatment Period (6 weeks) during which all patients will be randomized in a 1:1 ratio to receive either ITI-1284 or placebo;
- Safety Follow-up Period (30 days) during which all patients will return for a safety follow-up visit approximately 30 days after the last dose of study drug.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Can understand the nature of the trial and protocol requirements and provide signed informed consent, if in the judgement of the Investigator is deemed competent to provide consent or if patient is deemed not competent to provide informed consent, with the patient's assent (if capable), consent may be provided by an appropriate person (eg, patient's Legally Authorized Representative [LAR]) before the initiation of any study-specific procedures in accordance with local regulations
- •Meets clinical criteria for AD based on 2011 NIA-AA criteria and either:
- •Has a high likelihood for amyloid pathology consistent with AD, as confirmed by blood-based biomarker at Screening as detected by an appropriately validated test; or
- •Has documented confirmation of AD by cerebrospinal fluid (CSF) biomarker or amyloid positron emission tomography (PET) brain scan
- •Meets criteria for psychosis in accordance with the International Psychogeriatric Association (IPA) provisional consensus definition at Screening and Baseline
- •Scoring ≥ 2 on any item of the BEHAVE-AD Part A. Paranoid and Delusional Ideation item and/or Part B. Hallucinations item (ie, psychosis subscale) at Screening and Baseline
- •CGI-S score ≥ 4 at Screening and Baseline
- •Mini-Mental State Examination, 2nd Edition™: Standard Version (MMSE-2®:SV) score of 6 to 24 (inclusive) at Screening with sufficient verbal ability to understand and answer questions and comply with procedures
- •Has a designated caregiver (eg, relative, housemate, close personal friend, or professional caregiver)
排除标准
- •Psychotic symptoms that are primarily attributable to delirium, substance abuse, or another general-medical condition (for example, hypothyroidism) or has been diagnosed with one or more of the following psychiatric conditions:
- •Schizophrenia, schizoaffective disorder, or other psychotic disorder that is not related to Alzheimer's dementia
- •Bipolar disorder
- •Risk for suicidal behavior during the course of their participation in the study or is considered to be an imminent danger to themselves or others, in the opinion of the investigator, and/or as assessed by C-SSRS; or the patient has had 1 or more suicide attempts within 2 years prior to Screening
- •The patient is unable or unwilling to discontinue other drugs with known psychotropic properties or any non-psychotropic drugs with known or potentially significant central nervous system effects, as reviewed by the Sponsor or designee
- •The patient is hospitalized or receiving skilled nursing care for any medical condition other than dementia
- •The patient is bedridden or has any significant medical condition that is unstable and would either:
- •Place the patient at undue risk from study drug or undergoing study procedures; or
- •Interfere with the interpretation of safety or efficacy evaluations performed during the course of the study
- •The patient is in hospice or end-of-life care
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
ITI-1284
Experimental
干预措施: ITI-1284 (Drug)
结局指标
主要结局
BEHAVE-AD psychosis subscale score
时间窗: Week 6
The BEHAVE-AD psychosis subscale is comprised of 7 items from the paranoid and delusional ideations domain and 5 items from the hallucinations domain. The scale is rated on a 4--point scale of severity, from 0 (not present) to 3 (present, generally with an emotional and physical component). The maximum score for the psychosis subscale is 36.
次要结局
- CGI-S score(Week 6)
研究者
研究点 (80)
Loading locations...
相似试验
已完成
2 期
TC-5214 as add-on the Treatment of Major Depressive DisorderMajor Depressive DisorderDepressionNCT00692445Targacept Inc.574
已完成
3 期
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or DivalproexBipolar I DisorderNCT01358357Sumitomo Pharma America, Inc.965
招募中
2 期
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's DementiaNCT06651567Intra-Cellular Therapies, Inc.320
已完成
2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic InsomniaChronic InsomniaAdultsElderlyNCT01995838Eisai Inc.291
已完成
2 期
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's DiseaseParkinson DiseaseNCT05766813Intra-Cellular Therapies, Inc.79